| 1 |
35293692 | Program death ligand-1 immunocytochemistry in lung cancer cytological samples: A systematic review. | 2022 Jun |
1 |
| 2 |
35403870 | [Predictive immunocytochemistry in non-small cell lung carcinoma]. | 2022 May |
1 |
| 3 |
35562908 | PD-L1 Expression in Non-Small Cell Lung Cancer Specimens: Association with Clinicopathological Factors and Molecular Alterations. | 2022 Apr 19 |
1 |
| 4 |
35589508 | Malignant pleural effusion cell blocks are reliable resources for PD-L1 analysis in advanced lung adenocarcinomas: a concordance study with matched histologic samples. | 2022 Apr 22 |
1 |
| 5 |
33108706 | Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer. | 2021 Apr |
1 |
| 6 |
33683684 | Detection of Programmed Cell Death Ligand 1 Expression in Lung Cancer Clinical Samples by an Automated Immunohistochemistry System. | 2021 |
1 |
| 7 |
33683685 | Western Blot as a Support Technique for Immunohistochemistry to Detect Programmed Cell Death Ligand 1 Expression. | 2021 |
1 |
| 8 |
34178624 | Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report. | 2021 |
1 |
| 9 |
34206205 | Higher PD-L1 Immunohistochemical Detection Signal in Frozen Compared to Matched Paraffin-Embedded Formalin-Fixed Tissues. | 2021 Jun 22 |
1 |
| 10 |
31605792 | Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA. | 2020 Jan |
1 |
| 11 |
32079442 | Prognostic impact of PD-L1 in oropharyngeal cancer after primary curative radiotherapy and relation to HPV and tobacco smoking. | 2020 Jun |
1 |
| 12 |
33193888 | Programmed cell death-ligand 1 expression in stromal immune cells is a marker of breast cancer outcome. | 2020 |
1 |
| 13 |
33299472 | Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study. | 2020 |
2 |
| 14 |
29084060 | Characterization of PD-L1 Immunohistochemical Expression in Cell Blocks With Different Specimen Fixation and Processing Methods. | 2019 Feb |
1 |
| 15 |
29135534 | The Multiple Faces of Programmed Cell Death Ligand 1 Expression in Malignant and Nonmalignant Cells. | 2019 Apr |
3 |
| 16 |
30842953 | Formalin fixation on HER-2 and PD-L1 expression in gastric cancer: A pilot analysis using the same surgical specimens with different fixation times. | 2019 Feb 26 |
1 |
| 17 |
31030490 | Programmed Death Ligand 1 (PD-L1) Expression in Epithelial Ovarian Cancer: A Comparison of Type I and Type II Tumors | 2019 Apr 29 |
1 |
| 18 |
31050216 | Immunocytochemistry for predictive biomarker testing in lung cancer cytology. | 2019 May |
2 |
| 19 |
31092453 | Association Between Formalin Fixation Time and Programmed Cell Death Ligand 1 Expression in Patients With Non-Small Cell Lung Cancer. | 2019 May |
4 |
| 20 |
31186735 | MicroRNAs aid the assessment of programmed death ligand 1 expression in patients with non-small cell lung cancer. | 2019 Jun |
1 |
| 21 |
31261165 | PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer. | 2019 Sep |
1 |
| 22 |
28719380 | Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma. | 2018 Feb |
1 |
| 23 |
29189265 | Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma. | 2018 Jan |
2 |
| 24 |
29713584 | PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option? | 2018 May-Jun |
1 |
| 25 |
29767258 | PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma. | 2018 Jul |
1 |
| 26 |
29938855 | Programmed death-ligand 1 immunoexpression in matched biopsy and liquid-based cytology samples of advanced stage non-small cell lung carcinomas. | 2018 Dec |
1 |
| 27 |
30121940 | Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis. | 2018 Dec |
1 |
| 28 |
30323667 | Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8+ T-cell immune responses. | 2018 |
1 |
| 29 |
30386718 | Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma. | 2018 |
1 |
| 30 |
30527198 | Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer. | 2018 Dec |
1 |
| 31 |
31043303 | The usefulness of various cytologic specimen preparations for PD-L1 immunostaining in non-small cell lung carcinoma. | 2018 Nov - Dec |
2 |
| 32 |
27667773 | An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1. | 2017 Feb |
2 |
| 33 |
28363612 | Programmed Death - Ligand 1 Expression Distinguishes Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma from Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features. | 2017 Apr |
1 |
| 34 |
28922567 | Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining. | 2017 Dec |
1 |
| 35 |
28978000 | PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy. | 2017 Sep 15 |
1 |
| 36 |
29093818 | The novel 19G endobronchial USS (EBUS) needle samples processed as tissue "core biopsies" facilitate PD-L1 and other biomarker testing in lung cancer specimens: case report and the view point from the Respiratory Physician and the Pathologist. | 2017 Nov |
1 |
| 37 |
26511814 | Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma. | 2016 Apr |
1 |
| 38 |
26958083 | The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs. | 2016 |
1 |
| 39 |
27086918 | Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. | 2016 May 31 |
1 |
| 40 |
27166394 | Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma. | 2016 Sep 15 |
1 |
| 41 |
27333219 | Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer. | 2016 Jul |
1 |
| 42 |
27491898 | The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma. | 2016 Sep 2 |
1 |
| 43 |
27622038 | Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma. | 2016 Jul |
1 |
| 44 |
27717372 | Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. | 2016 Oct 8 |
1 |
| 45 |
25774992 | Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). | 2015 |
1 |
| 46 |
26037795 | The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. | 2015 Sep |
1 |
| 47 |
26317305 | Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. | 2015 Sep |
2 |
| 48 |
26546452 | PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. | 2015 Dec |
1 |